{
    "Trade/Device Name(s)": [
        "VIDAS\u00ae TOXO IgG Avidity Assay"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K101946",
    "Predicate Device Reference 510(k) Number(s)": [
        "K923166"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LGD"
    ],
    "Summary Letter Date": "May 13, 2011",
    "Summary Letter Received Date": "May 16, 2011",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3780"
    ],
    "Regulation Name(s)": [
        "Toxoplasma gondii Serological Reagents"
    ],
    "Analyte Class(es)": [
        "immunology",
        "microbiology",
        "serology"
    ],
    "Analyte(s)": [
        "Anti-toxoplasma IgG avidity"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VIDAS (VITEK ImmunoDiagnostic Assay System)"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked fluorescent assay (ELFA)",
        "Enzyme immunoassay (sandwich principle)"
    ],
    "Methodologies": [
        "Immunoassay",
        "Fluorescent detection"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for VIDAS TOXO IgG Avidity Assay, an automated ELFA assay to determine anti-toxoplasma IgG avidity in human serum.",
    "Indications for Use Summary": "Automated qualitative test to determine anti-toxoplasma IgG avidity in human serum to aid in presumptive exclusion of recent (\u22644 months) Toxoplasma gondii infection in pregnant women and patients with lymphadenopathy, used with VIDAS TOXO IgG II results.",
    "fda_folder": "Microbiology"
}